MIST
Milestone Pharmaceuticals Inc.
There isn't enough reported data to score MIST yet.
MIST Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MIST's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MIST PE Valuation
MIST has no meaningful PE right now: it lost money over the past year.
MIST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect MIST's losses to grow, with revenue declining. However, they disagree widely on these estimates.
MIST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.65 | +$0.18 |
| Q1 2026 | -$0.64 | +$0.13 |
| Q4 2025 | -$0.75 | -$0.08 |
| Q3 2025 | -$0.81 | $0.00 |
| Q2 2025 | -$0.83 | +$0.19 |
| Q1 2025 | -$0.77 | +$0.48 |
| Q4 2024 | -$0.67 | +$0.72 |
| Q3 2024 | -$0.81 | +$0.58 |
MIST is still losing money, but far less than before: $0.65 per share over the past year, against $1.70 at its worst in late 2020.
MIST Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4585% | N/A |
| Q1 2026 | -9942% | N/A |
MIST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$22.7M | -$10.2M |
| Q1 2026 | -$16.1M | -$2.1M |
| Q4 2025 | -$13.1M | -$6.2M |
| Q3 2025 | -$9.8M | -$2.7M |
| Q4 2024 | -$6.9M | +$3M |
| Q3 2024 | -$7M | +$5.2M |
| Q4 2023 | -$9.8M | +$3.1M |
| Q3 2023 | -$12.2M | -$502K |
MIST has burned cash in almost every quarter: −$62M over the past year, against −$40M the year before.
MIST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +46% | +39.5M shares |
| 3 years | +273% | +91.1M shares |
| 5 years | +317% | +94.7M shares |
| Available history | +408% | +100M shares |
MIST has 124M diluted shares, up 46% from a year ago.
MIST Net Leverage
MIST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MIST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 12.9 | Oversold |
MIST's weekly RSI is 33 (neutral) and its Stochastic is 13 (oversold).
MIST PE vs Healthcare Sector
MIST has no meaningful PE right now: it lost money over the past year.
MIST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.73 | 9.6% below |
| 20 week MA | $0.98 | 33% below |
| 50 week MA | $1.44 | 54% below |
| 100 week MA | $1.60 | 59% below |
| 200 week MA | $2.01 | 67% below |
MIST is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
MIST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.4 | $6.91 | -55% |
| 2021 | $6.91 | $7.04 | +1.9% |
| 2022 | $7.04 | $3.78 | -46% |
| 2023 | $3.78 | $1.67 | -56% |
| 2024 | $1.67 | $2.15 | +29% |
| 2025 | $2.15 | $2.08 | -3.3% |
| 2026 YTD | $2.08 | $0.66 | -68% |
MIST has finished lower in four of the last six years. It's down 68% so far in 2026.